You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Structure-based discovery of dopamine D1 receptor selective small molecule ligands

    SBC: CONFOMETRX, INC.            Topic: 101

    Dopamine receptors are a family of G protein-coupled receptors (GPCRs), and can be further divided into D1-like (D1 and D5) and D2-like (D2, D3 and D4) subfamilies. In this proposal, we focus on D1 receptor, which is widely expressed in brain at high levels. Modulation of D1 activity is implicated in the treatment of many psychiatric and neurological disorders, such as schizophrenia, attention def ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid diagnostic to determine CMV serological status

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    The goal of this project is to develop a diagnostic that can support the enrollment of seronegative individuals in clinical trials of candidate cytomegalovirusCMVvaccinesCongenital CMV infection is one of the leading causes of non genetic birth defects worldwideIf a successful vaccine can be brought to marketit will have a significant impact on the number of babies born with hearing and vision los ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. TOPIC 359: A DEVICE PROTOTYPE FOR ISOLATION OF MELANOMA EXOSOMES FOR DIAGNOSTICS AND TREATMENT MONITORING

    SBC: Aethlon Medical, Inc.            Topic: NCI

    The proposed work aims to develop a pre commercial prototype of an exosome isolation device to be used in clinical diagnostic laboratoriesWe will advance the device to facilitate exosome isolation for downstream liquid biopsy tests requiring analysis of proteinDNAor microRNAwhich rely upon acquisition of intact and pure exosomesThe device strategy will be designed to isolate total exosomes and the ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. TOPIC 360: A SIMPLE END-TO-END SYSTEM FOR SERIAL CELL SORTING AND MANIPULATION USING A SINGLE CONTAINER- MOONSHOT

    SBC: Diagnologix, LLC            Topic: NCI

    Chemotherapy may control but rarely cure metastatic cancersRemarkablymodern immunotherapiesincluding cell based therapieshave cured metastatic melanomas and other types of cancersA major challenge for all cell therapies in general is the need to develop cost effective and efficient manufacturing and delivery capabilitiesWe have recently established an innovative cell isolation technology by applyi ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. TOPIC 353: HIGHLY ACCURATE LOW COST CTDNA DIAGNOSTICS WITH MAGNETIC NANOPARTICLE ENABLED AUTOMATED SAMPLE PREP- MOONSHOT

    SBC: NVIGEN            Topic: NCI

    The goal of the research is to develop a highly accurateautomatedand low cost ctDNA test to monitor efficacy of treatment of metastatic breast cancer patients by identifying the emergence of certain DNA mutations in plasma samplesThere is growing evidence that the presence of certain DNA mutations in the blood stream correlates with breast cancer becoming resistance to hormone treatmentNVIGEN will ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. IGF::OT::IGF TOPIC 372 DEVELOPMENT AND VALIDATION OF NON-MOUSE REAGENTS TO ENABLE PRECLINICAL DEVELOPMENT OF NOVEL THERAPEUTICS- MOONSHOT

    SBC: SYNBAL, INC.            Topic: NCI

    In this Fast track SBIR grant we aimby the end of Phase IIto prepare and commercialize a fully humanized rat with Knock out of many rat drug metabolism related CYPsinout Rat Drug Metabolism CYPModeland Knock in of the human counterpartIN PHASE I we will develop an Active GenesGene DriveAG GDrata rat with a properly configured Casto power Active GeneticsAGANDwe will prepare the first CYPKout KinCYP ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. CANNABIS IMPAIRMENT DETECTION APPLICATION (CIDA) (T163). SBIR PHASE II. POP: 9/20/2019-9/19/2021. N44DA-19-1218.

    SBC: ADVANCED BRAIN MONITORING, INC.            Topic: NIDA

    Under this Small Business Innovation ResearchSBIRPhase I projectResearch Topicthe Contractor will develop a portableeasily applied system incorporating a neuropsychological test protocol to detect cannabis impairment

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Affordable wireless recording for mice

    SBC: Jinga-hi Inc.            Topic: 101

    Project Summary Mice offer a powerful genetic model system, thus are the single most used animal model in neuroscience. Despite potential benefits of wireless recording (more flexible, safer, and more natural in vivo neural recording), adoption of wireless recording in the neuroscience community for mice for a wider neuroscience community had been slow, due to the engineering complexity to enable ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Commercial Platform for Discovery and Validation of Key Microbial Metabolites in CNS Disorders

    SBC: Second Genome, Inc.            Topic: NIDA

    Despite a wealth of continued funding and ever emerging advancements in diagnostic and therapeutic technologies, the burden of central nervous system (CNS) disorders remains substantial. The cost of Substance Use Disorder (SUD) alone is estimated at andgt; $181 billion (2002). The findings of numerous efforts tasked with identifying risk factors and causative agents of SUD suggest that vulnerabili ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic Antibody for RSV IIB

    SBC: Trellis Bioscience, LLC            Topic: R

    Abstract Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract disease in infants, leading annually to ~200,000 deaths and 3-4 million hospitalizations worldwide. Close to $1 billion has been invested by the RSV community over the past two decades in clinical trials seeking to improve upon the marketed monoclonal antibody Synagis®, which is only approved for prop ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government